Siemens Healthineers and Sysmex agree to supply haemostasis instruments, reagents as OEMs
Siemens Healthineers has signed a global OEM agreement on haemostasis products with Sysmex Corporation under which each company will supply the other with their products in the diagnostic field of haemostasis on an OEM basis.
Siemens Healthineers and Sysmex provide, among other things, haemostasis products used in testing for blood clotting disorders, preoperative bleeding risk management, and the monitoring of patients receiving anticoagulant therapy medications. The OEM agreement positions each company to distribute – globally and individually – under their respective brands the companies’ combined portfolio of haemostasis instruments and reagents, in combination with their own wider portfolios of products and services. Going forward, the companies will each individually offer effective solutions to laboratories worldwide that build on their respective strengths based on one of the world’s most extensive haemostasis product portfolios realized through the collaboration.
“Siemens Healthineers and Sysmex have built a solid haemostasis partnership for more than 25 years,” said Sharon Bracken, Head of Diagnostics for Siemens Healthineers. “The time has come to offer one of the world’s most extensive product portfolios achieved through mutual OEM supply to benefit customers and patients worldwide. With the OEM agreement, we will more effectively deliver quality and comprehensive haemostasis testing solutions to laboratories of all sizes across the world.”
“Making our long-standing partnership with Siemens Healthineers even more sustainable, we remain committed to further enhance the value of haemostasis testing as a global leader,” said Kenji Tachibana, Member of the Managing Board and Senior Executive Officer, Senior Managing Director of Sysmex. “We will individually offer laboratories worldwide proprietary solutions with the benefit of our respective expertise and service portfolio, providing customers with access to the broadest set of solutions in the evolving market.”
Since entering into a global agreement on distribution, sales, and services for haemostasis products in 1995, the two companies have built a solid partnership becoming one of the leading solution providers in the global haemostasis segment. During this period, the companies also have expanded their capabilities and enhanced their individual strengths through innovation in their respective portfolios.
In recent years, demand for haemostasis testing has increased and grown more diverse because of a rise in thrombotic diseases stemming from lifestyle diseases, the development of new blood preparations, the use in testing to predict COVID-19 severity, as well as increased demands for standardization, IT connectivity, and quality improvement in testing.
